medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2008, Number 2

<< Back Next >>

Ann Hepatol 2008; 7 (2)

The role of microRNAs in primary liver cancer

Varnholt H

Language: Spanish
References: 96
Page: 104-113
PDF size: 168.24 Kb.


Text Extraction

Small RNA molecules such as microRNAs, for many years considered to be superfluous genomic material, are now known to play important regulatory roles in apoptosis, cell proliferation and differentiation, angiogenesis and thus in carcinogenesis. Primary liver carcinomas such as hepatocellular carcinomas, cholangiocarcinomas and mixed variants show a rising incidence with high mortality among affected patients but lack effective targeted therapies except the new multiple kinase inhibitor Sorafenib. This review elucidates the recent contributions of miRNA gene expression analyses to a better understanding of the complex molecular interactions in liver carcinogenesis and highlights their future promise to provide novel tools for improved diagnostics, more accurate prognostic assessment and tailored molecular therapies in liver cancer.


REFERENCES

  1. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism and function. Cell 2004; 116: 281-97

  2. Calin GA, Croce CM. MicroRNA-Cancer Connection: The Beginning of a New Tale. Cancer Res 2006; 66: 7390-4.

  3. Dalmay T, Edwards DR. MicroRNAs and the hallmarks of cancer. Oncogene 2006; 25: 6170-5.

  4. Cummins JM, Velculescu VE. Implications of micro-RNA profiling for cancer diagnosis. Oncogene 2006; 25: 6220-7.

  5. Kent OA, Mendell JT. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 2006; 25: 6188-96.

  6. Pfeffer S, Voinnet O. Viruses, microRNAs and cancer. Oncogene 2006; 25: 6211-9.

  7. Weber MJ. New human and mouse microRNA genes found by homology search. FEBS J 2005; 272: 59-73.

  8. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, et al. A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia. N Engl J Med 2005; 353: 1793-801.

  9. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev 2005; 6: 376-85.

  10. Engels BM, Hutvagner G. Principles and effects of microRNA-mediated post-transcriptional gene regulation. Oncogene 2006; 25: 6163-9.

  11. Hayashita Y, Osada H Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Yatabe Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005; 65: 9628-32.

  12. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human microRNA targets. Plos Biol 2004; 2: 1862-79.

  13. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004.

  14. Lee YS, Kim HK, Chung S, Kim KS, Dutta A. Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation. J Biol Chem 2005; 17: 16635-41.

  15. Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, Barzilai A, et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 2005; 37: 766-70.

  16. Shingara J, Keiger K, Shelton J, Losinchai-Wolf W, Powers P, Conrad R, Brown D, et al. An optimized isolation and labelling platform for accurate microRNA expression profiling. RNA 2005; 11: 1461-70.

  17. Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W, Jacob ST, et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006; 99: 671-8.

  18. Liang Y, Ridzon D, Wong L, Chen C. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 2007; 8: 166.

  19. Jopling CL, Norman KL, Sarnow P. Positive and negative modulation of viral and cellular mRNAs by liver-specific microRNA miR-122. Cold Spring Harb Symp Quant Biol 2006; 71: 369-76.

  20. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of Hepatitis C virus RNA abundance by a liver-specific microRNA. Science 2005; 309: 1577-81.

  21. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG, Calin GA, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007; 67: 6092-9.

  22. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-54.

  23. Lee EJ, Baek M, Gusev Y, Brackett DJ, Nuovo GJ, Schmittgen TD. Systematic evaluation of microRNA processing patterns in tissues, cell lines, and tumors. RNA 2008; 14: 1-8.

  24. Sassen S, Miska EA, Caldas C. MicroRNA – implications for cancer. Virchows Arch 2008; 452: 1-10.

  25. Hunt JP, Varnholt H. Mixed hepatocellular-cholangiocarcinoma may derive from «hepatogones». Hepatobiliary Pancreat Dis Int 2008; 358: 852.

  26. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.

  27. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular carcinoma. Gastroenterology 2007; 133: 647-58.

  28. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Gen 2002; 31: 339-46.

  29. Motola-Kuba D, Zamora-Valdes D, Uribe M, Mendez-Sanchez N. Hepatocellular carcinoma. An overview. Ann Hepatol 2006; 5: 16-24.

  30. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006; 25: 3834-47.

  31. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, Durnez A, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004; 40: 667-76.

  32. Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Sem Liver Dis 2005; 25: 133-42.

  33. Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, Roberts LR, et al. Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 2008; 14: 419-27.

  34. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 2005; 25: 212-25.

  35. Mott JL, Kobayashi S, Bronk SF, Gores GJ. miR-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007; 26: 6133-40.

  36. Meng F, Wehbe-Janek H, Henson R, Smith H, Patel T. Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene 2008; 27: 378-86.

  37. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006; 130: 2113-29.

  38. Meng F, Henson R, Wehbe-Janek H, Smith H, Ueno Y, Patel T. The microRNA let-7a modulates interleukin-6-dependent STAT-3 survival signalling in malignant human cholangiocytes. J Biol Chem 2007; 282: 8256-64.

  39. Weimann A, Varnholt H, Schlitt HJ, Lang H, Flemming P, Hustedt C, Tusch G, et al. Retrospective analysis of prognostic factors after liver resection and transplantation for cholangiocellular carcinoma. Br J Surg 2000; 87: 1182-7.

  40. Ross JS, Carlson JA, Brock G. miRNA: The new gene silencer. Am J Clin Pathol 2007; 128: 830-6.

  41. He X, He L, Hannon GJ. The guardian’s little helper: MicroRNAs in the p53 tumor suppressor network. Cancer Res 2007; 67: 11099-101.

  42. Yang J, Zhou F, Xu T, Deng H, Ge YY, Zhang C, Li J, et al. Analysis of sequence variations in 59 microRNAs in hepatocellular carcinomas. Mutat Res 2008; 638: 205-9.

  43. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-66.

  44. Caldas C, Brenton JD. Sizing up miRNAs as cancer genes. Nat Med 2005; 11: 712-4.

  45. Hutvagner G. MicroRNAs and cancer: issue summary. Oncogene 2006; 25: 6154-5.

  46. Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 2006; 94: 776-80.

  47. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM. MicroRNA expression and function in cancer. Trends Mol Med 2006; 12: 580-7.

  48. Akao Y, Nakagawa Y, Naoe T. MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep 2006; 16: 845-50.

  49. Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N, Abajo A, et al. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 2006; 5: 29.

  50. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-70.

  51. Michael MZ, O´Connor SM, Van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003; 1: 882-91.

  52. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9: 189-98.

  53. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagi R, Volinia S, Calin GA, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 2005; 102: 19075-80.

  54. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005; 65: 6029-33.

  55. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102: 13944-9.

  56. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-8.

  57. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with a shortened postoperative survival. Cancer Res 2004; 64: 3753-6.

  58. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006; 25: 2537-45.

  59. Roessler S, Budhu A, Wang XW. Future of molecular profiling of human hepatocellular carcinoma. Future Oncol 2007; 3: 429-39.

  60. Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP, Odenthal M. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 2008; 47: 1223-32.

  61. Pogribny IP, Tryndyak VP, Boyko A, Rodriguez-Juarez R, Beland FA, Kovalchuk O. Induction of microRNAome deregulation in rat liver by long-term tamoxifen exposure. Mutat Res 2007; 619: 30-7.

  62. Huang YS, Dai Y, Yu XF, Bao SY, Yin YB, Tang M, Hu CX. Microarray analysis of microRNA expression in hepatocellular carcinoma and non-tumorous tissues without viral hepatitis. J Gastroenterol Hepatol 2008; 23: 87-94.

  63. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, Ju J. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 2007; 13: 1668-74.

  64. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafre SA, Farace MG. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 2007; 282: 23716-24.

  65. Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, Zucman-Rossi J. MicroRNA profiling in hepatocellular tumors is associated to clinical features an oncogene/tumor suppressor gene mutations. Hepatology 2008; (Epub ahead of print).

  66. Wang Y, Lee AT, Ma JZ, Wang J, Ren J, Yang Y, Tantoso E, et al. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem 2008; March 4 (Epub ahead of print).

  67. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, et al. Expression profiling identifies microRNA signatures in pancreatic cancer. Int J Cancer 2007; 120: 1046-54.

  68. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-61.

  69. Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, Calin GA, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 2006; 24: 4677-84.

  70. Tetzlaff MT, Liu A, Xu X, Master SR, Baldwin DA, Tobias JW, Livolsi VA, et al. Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocr Pathol 2007; 18: 163-73.

  71. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2007; Oct 29 (Epub ahead of print).

  72. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425-36.

  73. Zhu S, Wu H, Nie D, Sheng S, Mo YY. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 2008; February 12 (Epub ahead of print).

  74. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, Dang CV, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008; 40: 43-50.

  75. O´Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT: c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435: 839-43.

  76. Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S, Yoshida Y, et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 2004; 64: 3087-95.

  77. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, et al. A microRNA polycistron as a potential human oncogenes. Nature 2005; 435: 828-33.

  78. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, Furth EE, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006; 38: 1060-5.

  79. Ma L, Teruya-Felstein, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449: 682-9.

  80. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451: 147-52.

  81. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R, et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007; 72: 397-4021.

  82. Kong Y, Han JH. MicroRNA: Biological and computational perspective. Genomics Proteomics Bioinformatics 2005; 3: 62-72.

  83. Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA, Xu C, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004; 1: 106-13.

  84. Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A. miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol 2008; 48: 648-56.

  85. Krützfeld J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M. Silencing of microRNAs in vivo with ‘antagomirs’. Nature 2005; 438: 685-9.

  86. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, Watts L, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Met 2006; 3: 87-98.

  87. Etiemble J, Moroy T, Jacquemin E, Tiollais P, Buendia MA. Fused transcripts of c-myc and a new cellular locus, hcr, in a primary liver tumor. Oncogene 1989; 4: 51-7.

  88. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tusch T. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12: 735-9.

  89. Elmen J, Lindow M, Silahtaroglu A, Bak M, Christensen M, Lind-Thomsen A, Hedtjärn M, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucl Acids Res 2008; 36: 1153-62.

  90. Fabiani MM, Gait MJ. miR-122 targeting with LNA/2´-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. RNA 2008; 14: 1-11.

  91. Shan Y, Zheng J, Lambrecht RW, Bonkovsky HL. Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology 2007; 133: 1166-74.

  92. Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, Zanetti KA, et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008; 47: 897-907.

  93. Yang H, Kong W, He L, Zhao JJ, O´Donnell JD, Wang J, Wenham RM, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68: 425-33.

  94. Stutes M, Tran S, DeMorrow S. Genetic and epigenetic changes associated with cholangiocarcinoma: From DNA methylation to microRNAs. World J Gastroenterology 2007; 13: 6465-9.

  95. Christoffersen NR, Silahtaroglu A, Orom UA, Kauppinen S, Lund AH. miR-200b mediates post-transcriptional repression of ZFHX1B. RNA 2007; 13: 1172-8.

  96. Fukushima T, Hamada Y, Yamada H, Horii I. Changes of micro-RNA expression in rat liver treated by acetaminophen or carbon tetrachloride – regulating role of micro-RNA for RNA expression -. J Tox Sci 2007; 32: 401-9.




2020     |     www.medigraphic.com